Zobrazeno 1 - 10
of 2 742
pro vyhledávání: ''
Autor:
Stefanie D. Krens, Wim van Boxtel, Carla M.L. van Herpen, Sasja F. Mulder, Frank G A Jansman, Maike J. M. Uijen, Ingrid M.E. Desar, Nielka P. van Erp
Publikováno v:
International Journal of Cancer, 150, 308-316
International Journal of Cancer, 150, 2, pp. 308-316
International Journal of Cancer, 150(2), 308-316. Wiley
International Journal of Cancer, 150, 2, pp. 308-316
International Journal of Cancer, 150(2), 308-316. Wiley
Contains fulltext : 249093.pdf (Publisher’s version ) (Open Access) Cabozantinib is registered in fixed 60 mg dose. However, 46% to 62% of patients in the registration studies needed a dose reduction due to toxicity. Improved clinical efficacy has
Autor:
John B. A. G. Haanen, Maureen J.B. Aarts, Michel W.J.M. Wouters, Albert J. ten Tije, Astrid A M van der Veldt, Karijn P M Suijkerbuijk, Rozemarijn S. van Rijn, Alfons J.M. van den Eertwegh, Liesbeth C. de Wreede, Ellen Kapiteijn, Geke A. P. Hospers, Franchette W P J van den Berkmortel, Jacobus J.M. van der Hoeven, Gerard Vreugdenhil, Michiel C T van Zeijl, Jan-Willem B de Groot, Djura Piersma
Publikováno v:
International Journal of Cancer, 150(2), 317-326. Wiley-Liss Inc.
International Journal of Cancer, 150(2), 317-326. Wiley
International Journal of Cancer, 150(2), 317-326. WILEY
International Journal of Cancer, 150, 2, pp. 317-326
International Journal of Cancer, 150, 317-326
van Zeijl, M C T, van den Eertwegh, A J M, Wouters, M W J M, de Wreede, L C, Aarts, M J B, van den Berkmortel, F W P J, de Groot, J-W B, Hospers, G A P, Kapiteijn, E, Piersma, D, van Rijn, R S, Suijkerbuijk, K P M, ten Tije, A J, van der Veldt, A A M, Vreugdenhil, G, van der Hoeven, J J M & Haanen, J B A G 2022, ' Discontinuation of anti-PD-1 monotherapy in advanced melanoma—Outcomes of daily clinical practice ', International Journal of Cancer, vol. 150, no. 2, pp. 317-326 . https://doi.org/10.1002/ijc.33800
International Journal of Cancer, 150(2), 317-326. Wiley
International Journal of Cancer, 150(2), 317-326. WILEY
International Journal of Cancer, 150, 2, pp. 317-326
International Journal of Cancer, 150, 317-326
van Zeijl, M C T, van den Eertwegh, A J M, Wouters, M W J M, de Wreede, L C, Aarts, M J B, van den Berkmortel, F W P J, de Groot, J-W B, Hospers, G A P, Kapiteijn, E, Piersma, D, van Rijn, R S, Suijkerbuijk, K P M, ten Tije, A J, van der Veldt, A A M, Vreugdenhil, G, van der Hoeven, J J M & Haanen, J B A G 2022, ' Discontinuation of anti-PD-1 monotherapy in advanced melanoma—Outcomes of daily clinical practice ', International Journal of Cancer, vol. 150, no. 2, pp. 317-326 . https://doi.org/10.1002/ijc.33800
Contains fulltext : 287666.pdf (Publisher’s version ) (Open Access) There is no consensus on the optimal treatment duration of anti-PD-1 for advanced melanoma. The aim of our study was to gain insight into the outcomes of anti-PD-1 discontinuation,
Autor:
Peter Malfertheiner, Alexander Stein, Ingo Tamm, Salah-Eddin Al-Batran, PaFLO investigators, Anica Högner, Nils Homann, Axel Hinke, Kirstin Breithaupt, Jens T. Siveke, Dietrich Gläser, Peter C. Thuss-Patience, Prisca Bartels, Mario Lorenz, Arndt Vogel
Publikováno v:
International Journal of Cancer. 150:1007-1017
VEGF inhibition in gastric cancer has a proven benefit in the second line setting. Pazopanib, an oral tyrosine kinase inhibitor, selectively inhibits VEGFR-1, -2 and -3, c-kit and PDGF-R resulting in inhibition of angiogenesis. This open-label random
Autor:
Marco Pavesi, Moisés Mira Flores, Aurea Duran, Josep Gumà, Alessandra Pranzo, Alexis Serikoff, Bernard Rappe, Angus Robinson, Serena Hilman, Benoit Baron, Louis-Marie Dourthe, D. Mott, Steven Joniau, M. Herdman, Stéphane Mallick, Roberto Bordonaro, Maria De Santis, Ugo De Giorgi, Heather Payne
Publikováno v:
International Journal of Cancer. 150:837-846
In randomized clinical trials, the androgen-receptor inhibitor enzalutamide has demonstrated efficacy and safety in metastatic castration-resistant prostate cancer (mCRPC). This study captured efficacy, safety and patient-reported outcomes (PROs) of
Autor:
Gangling Zhang, Min-Yi Cheng, Mei Yang, Ci-Qiu Yang, Jie Li, Yin Cao, Teng Zhu, Hong-Fei Gao, Ying Lin, Zhenzhen Liu, Zhi-Yong Wu, Fei Ji, Jieqing Li, Kun Wang, Liulu Zhang
Publikováno v:
International Journal of Cancer. 150:654-662
Previous studies have shown that the addition of carboplatin to neoadjuvant chemotherapy improved the pathologic complete response (pCR) rate in patients suffering from triple-negative breast cancer (TNBC), and patients who obtained a pCR could achie
Autor:
Osvaldo Espin-Garcia, Geoffrey Liu, Kouros Owzar, Maura N Dickler, Monica M. Bertagnolli, Danyu Lin, Chen Jiang, Amy S. Etheridge, Federico Innocenti, Alan P. Venook, Heinz-Josef Lenz, Hedy L. Kindler, Mark J. Ratain, Jin Wang, Alexander B. Sibley, Wei Xu, Julia C F Quintanilha
Publikováno v:
Int J Cancer
Germline variants might predict cancer progression. Bevacizumab improves overall survival (OS) in patients with advanced cancers. No biomarkers are available to identify patients that benefit from bevacizumab. A meta-analysis of genome-wide associati
Autor:
Banlanjo Abdulaziz Umaru, Hirofumi Miyazaki, Shuhan Yang, Yui Yamamoto, Shuhei Kobayashi, Tunyanat Wannakul, Yuji Owada, Yu Takahashi, Yoshiteru Kagawa, Kaname Sekino
Publikováno v:
International Journal of Cancer. 150:152-163
Plasmacytoid dendritic cells (pDCs) promote viral elimination by producing large amounts of Type I interferon. Recent studies have shown that pDCs regulate the pathogenesis of diverse inflammatory diseases, such as cancer. Fatty acid-binding protein
Autor:
Xiaojing Zhang, Zhiqiang Meng, Shanzhi Gu, Shukui Qin, Zhendong Chen, Xiao Zhang, Linna Wang, Xinni Chen, Jianjun Zou, Ying Liu, Jianping Xiong, Zhenggang Ren
Publikováno v:
International Journal of Cancer. 149:1944-1954
Biliary tract cancer (BTC) is a highly malignant tumor with limited treatment options and poor prognosis. Our study aimed to evaluate camrelizumab plus oxaliplatin-based chemotherapy as first-line therapy for advanced BTC. In this multicenter, open-l
Autor:
Mohammad Ghasemi, Andrew Goey, John Wilton, Wiam Bshara, Adrienne Groman, Renuka Iyer, Christos Fountzilas, Wen Wee Ma, Mateusz Opyrchal, Alex A. Adjei, Rachel Evans, Kristopher Attwood
Publikováno v:
Int J Cancer
In this phase I, dose-escalation study, we sought to determine the maximum tolerated dose (MTD) of the anaplastic lymphoma kinase/c-ROS oncogene 1 receptor (ALK/ROS1) inhibitor ceritinib in combination with gemcitabine-based chemotherapy in patients
Autor:
Christopher Wills, Katie Watts, Victoria Gray, Valentina Escott-Price, David J. Kerr, Hannah West, Claire Palles, Richard Kaplan, Nada Al-Tassan, Ayman Madi, Tim Maughan, Rachel Kerr, Jeremy Peter Cheadle, Richard S. Houlston
Publikováno v:
International Journal of Cancer. 149:1713-1722
Chemotherapies administered at normal therapeutic dosages can cause significant side-effects and may result in early treatment discontinuation. Inter-individual variation in toxicity highlights the need for biomarkers to personalise treatment. We sou